Compound Screening TRIZ Cases

Modified Fc regions enable antigen-binding molecules to exert cytotoxic activity only in tumor microenvironments, reducing side effects against normal tissues.

Disrupting extracellular cyclophilin A binding to CD147 inhibits multiple myeloma cell migration and proliferation in the bone marrow.

Forced expression of Ngn2, Lhx3, and Isl1 in pluripotent stem cells drives rapid, synchronous motor neuron differentiation for reliable disease modeling.

A screening method identifies compounds that inhibit the conversion of cysteine glycine conjugates into volatile sulfur compounds.

Targeting glutamate transporter GLT1 preserves beta cell mass and prevents hyperglycemia progression by blocking autoantibody binding.

Segmented detection using immobilized and labeled antigens resolves low sensitivity and high false positive rates in insulin receptor family assays.

Peptide agents bind to unbundled fibrils of Huntingtin exon 1, inhibiting aggregation that causes severe symptoms and early onset.

Disulfide bonds stabilize chimeric peptides against aggregation, maintaining structural integrity and antiviral efficacy.

Detect RelB phosphorylation at serine 472 to assess non-canonical NF-kB pathway activation and cell migration potential.

Administering human cerebrospinal fluid into rodent cerebral ventricles to evaluate cognitive function via behavioral pharmacological techniques.

Bacterial siRNA expression systems resolve low yield and off-target effects by integrating transcription and stabilization within a single host.

A microtiter plate assay scans mutant ligands against GPCRs to identify binding affinities.

A thiol-ene based polymer device enables stable in-vitro drug evaluation through reduced material sorption.

Testing OR6M1 and OR6V1 expression replaces subjective assessment with molecular data, resolving the lack of objective diagnostic capability.

TOM34 expression levels diagnose colon cancer while siRNA suppression inhibits tumor growth.

Small molecule compounds inhibit HP1-mediated heterochromatin formation, reducing H3K9me marks to treat cancers lacking effective epigenetic therapies.

Thiol quantification reagent bonds to free thiols forming conjugates for biophysical measurement of ligand binding kinetics.

Screening method identifies compounds modulating EphA4 processing via gamma-secretase, enabling targeted Alzheimer's therapy development.

Inhibiting PAPD5 prevents harmful oligo-adenylated TERC accumulation, restoring telomerase activity and elongating telomeres in PARN-mutant cells.

Infrared spectroscopy detects protein conformational changes to replace unreliable genetic markers with direct functional readouts.

Multimerized bait proteins identify host interactors to decrease viral infection by 40%.

A screening method uses the alpha value to identify muscarinic M1 receptor positive allosteric modulators with reduced cholinergic side effects.

Fluorescent AAV vectors measure antibody blockage via reporter signals, eliminating pathogenic adenovirus risks and enabling safe high-throughput screening.

Molecular genotypic detection replaces phenotypic inspection to improve flesh quality prediction accuracy and selection efficiency.

Segmented FISH probes and PCR primers detect PKN1 fusions, resolving the trade-off between detection specificity and method complexity.

Heterologous OR7D4 expression systems resolve research complexity by enabling precise olfactory sensation modulation through targeted siRNA duplexes.

An AI system analyzes in-vitro human hematopoietic microphysiology systems to evaluate drug immune responses.

A Slit-Robo composition activates beta-catenin to promote muscle differentiation and mass gain.

A compound modulates non-native protein-protein interactions in coronavirus nucleocapsid proteins to inhibit viral replication.

Cell-based assays detect human T2R receptor activation by bitter ligands, enabling identification of compounds that block specific taste responses.

Dynamic BH3 profiling measures apoptotic sensitivity in non-cancerous cells to detect toxic agents rapidly.

High pmCiC expression in cancer cells provides a reliable diagnostic marker and selective therapeutic target.

Screening identified compounds to block hT2R8, hT2R14, and hT2R54 receptors reduces bitter aftertaste intensity in coffee compositions.

Oxygen scavenging systems extend fluorophore lifetimes to observe ligand-dependent conformational dynamics in membrane proteins.

Modular CAR libraries with barcode tracking identify improved receptors to overcome limited solid tumor efficacy.

Selecting test substances to activate specific olfactory receptors for targeted odor suppression.

Molecular signatures predict BRAF melanoma response to MAPK inhibitors, enabling personalized treatment strategies that address acquired resistance.

Sortase-mediated ligation creates uniformly phosphorylated chimeric GPCRs, resolving low throughput and artifact issues in allosteric modulator screening.

Single-sample biomarker analysis predicts disease progression without complex fasting procedures.

Modifying APOBEC1 amino acids alters DNA binding affinity to minimize off-target mutations.

Elastic silicone bandages shield wounds from mechanical stress to inhibit keloid formation.

A cell culture plate uses nanofibrillar cellulose hydrogel barriers to separate compartments while allowing molecular diffusion.

Peptides targeting VQIINK and VQIVYK regions bind tau protein to form stable complexes, reducing fibril levels in Alzheimer's disease models.

A CRISPR-Cas9 method constructs a PD-1 gene-modified humanized mouse model using homologous recombination to replace specific mouse sequences with human DNA fragments.

An alpha effect nucleophile sensor achieves rapid detection at 100 ppb without bulky instrumentation.

ATP11B biomarkers replace invasive colonoscopy with rapid biochemical assays, reducing patient risk and healthcare costs.

A fluorescence resonance energy transfer method measures candidate antibody binding to bring effector and target cells into close proximity.

A cell-free assay identifies PARP-1 inhibitors by measuring poly(ADP)-ribose production during histone H4-dependent activation.